MARKET

VBLT

VBLT

VASCULAR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.100
0.000
0.00%
Closed 16:00 09/24 EDT
OPEN
2.120
PREV CLOSE
2.100
HIGH
2.140
LOW
2.060
VOLUME
161.32K
TURNOVER
--
52 WEEK HIGH
3.170
52 WEEK LOW
1.012
MARKET CAP
130.97M
P/E (TTM)
-4.1330
1D
5D
1M
3M
1Y
5Y
LCID, SDC and ABCL among pre market gainers
Corvus Pharmaceuticals (NASDAQ:CRVS) +56%. Innate Pharma (NASDAQ:IPHA) +32% Monalizumab data from COAST trial presented at ESMO Congress 2021 Surface Oncology (NASDAQ:SURF) +14%. BeiGene (NASDAQ:BGNE) +13% on positive DKN-01 + tislelizumab data in gastroes...
Seekingalpha · 09/17 12:21
BRIEF-VBL Therapeutics Says Data Safety Committee Gives Clearance To Continue Phase 3 Study Of Ovarian Cancer Treatment
reuters.com · 09/17 11:08
VBL Therapeutics Reports Independent Data Safety Monitoring Committee Provides Clearance To Continue OVAL Phase 3 Study Of VB-111 In Ovarian Cancer
The OVAL Phase 3 clinical trial evaluating VB-111 in platinum-resistant ovarian cancer has recruited more than 320 patients (>80 %) to date; Remains on track to complete enrollment in 1Q22 TEL AVIV, Israel,
Benzinga · 09/17 11:01
VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer
-- The OVAL Phase 3 clinical trial evaluating VB-111 in platinum-resistant ovarian cancer has recruited more than 320 patients (>80 %) to date;
GlobeNewswire · 09/17 11:00
VBL Therapeutics Gets Clearance to Advance Ongoing Phase 3 Trial of Ovarian Cancer Drug Candidate
MT Newswires · 09/17 08:19
VBL Therapeutics to Present at Upcoming Conferences
TEL AVIV, Israel, Sept. 10, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced the Company will present in the following upcoming industry conferences: H.C. Wainwright 23rd Annual Global Investment Conference Mon., Sept. 13, 2021Fires...
GlobeNewswire · 09/10 11:00
EDU, TAL and MMAT among pre market gainers
Vinco Ventures (NASDAQ:BBIG) +65%. Aterian (NASDAQ:ATER) +52%. Support.com (NASDAQ:SPRT) +45%. Affirm Holdings (NASDAQ:AFRM) +40% as Amazon to integrate pay-over-time into its cart Globalstar (NYSE:GSAT) +36% on report iPhone 13 may use satellite connectiv...
Seekingalpha · 08/30 12:31
VBL Therapeutics Resumes US Enrollment In OVAL Phase 3 Trial As FDA Authorizes Clinical Use Of VB-111 Batches Produced In Modiin Facility
U.S. FDA CMC clearance of VB-111 produced in Modiin, Israel facility an important milestone toward potential commercialization   OVAL Phase 3 trial evaluating VB-111 in platinum resistant ovarian cancer has
Benzinga · 08/30 11:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VBLT. Analyze the recent business situations of VASCULAR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VBLT stock price target is 5.38 with a high estimate of 7.00 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 39
Institutional Holdings: 4.33M
% Owned: 6.95%
Shares Outstanding: 62.37M
TypeInstitutionsShares
Increased
5
137.70K
New
6
1.58M
Decreased
4
141.74K
Sold Out
8
434.22K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Bennett Shapiro
Chief Executive Officer/Director
Dror Harats
Non-Executive Vice Chairman/Independent Director
Marc Kozin
Chief Financial Officer/Secretary
Amos Ron
Vice President - Operations
Eyal Breitbart
Vice President
Erez Feige
Vice President
Tami Rachmilewitz
Vice President
Naamit Sher
General Counsel
Ayelet Horn
Director
Alison Finger
Director
Michael Rice
Non-Executive Independent Director
Ruth Alon
Non-Executive Independent Director
Shmuel Ben Zvi
Non-Executive Independent Director
Ron Cohen
Non-Executive Independent Director
David Hastings
No Data
About VBLT
Vascular Biogenics Ltd. is Israel- based late-stage clinical biopharmaceutical company, focused on the discovery, development and commercialization of treatments for cancer. VBL’s clinical pipeline is based on two distinct platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. The Company has developed two programs based on these platforms an oncology program and an anti-inflammatory program. The Company’s lead oncology product VB-111, is a targeted anti-cancer gene-therapy agent that is positioned to potentially treat a wide range of solid tumors. VBL has also developed platform of investigational orally-available small molecules, designated Lecinoxoids, for the treatment of chronic immune-related indications.

Webull offers kinds of Vascular Biogenics Ltd stock information, including NASDAQ:VBLT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VBLT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VBLT stock methods without spending real money on the virtual paper trading platform.